Xilio Therapeutics (XLO) Preferred Stock Liabilities (2020 - 2021)

Xilio Therapeutics has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $222.9 million for Q3 2021.

• In Q3 2021, Preferred Stock Liabilities rose 346.2% year-over-year to $222.9 million; the TTM figure through Sep 2021 stood at $222.9 million (up 346.2% YoY), while the FY2020 annual figure was $78.0 million, changed N/A from the prior year.
• Preferred Stock Liabilities came in at $222.9 million for Q3 2021 at Xilio Therapeutics, up from $100.2 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $222.9 million in Q3 2021 to a low of $50.0 million in Q3 2020.